Trial reportJournal of the American Heart Association2026
Changes in Circulating Biomarkers in Patients With Ischemic Heart Failure After Treatment With Autologous Mesenchymal Stromal Cells and c-Kit-Positive Cardiac Cells, Alone or in Combination: Results From the Cardiovascular Cell Therapy Research Network CONCERT-HF Clinical Trial.
Trial report in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02501811 (A Phase II, Randomized, Placebo-Controlled Study of the Safety, Feasibility, & Efficacy of Autologous Mesenchymal Stem Cells & C-kit+ Cardiac Stem Cells, Alone or in Combination, Administered Transendocardially in Subjects With Ischemic HF), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase II, Randomized, Placebo-Controlled Study of the Safety, Feasibility, & Efficacy of Autologous Mesenchymal Stem Cells & C-kit+ Cardiac Stem Cells, Alone or in Combination, Administered Transendocardially in Subjects With Ischemic HF
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn ischemic heart failure, the biological mechanisms underlying the benefits of mesenchymal stromal cells (MSCs) and c-kit-positive cardiac progenitor cells (CPCs) remain incompletely understood.
methodsIn this predefined secondary biomarker analysis of 96 patients from the multicenter, randomized, double-blind, placebo-controlled Cardiovascular Cell Therapy Research Network CONCERT-HF (Combination of Mesenchymal and c-Kit+ Cardiac Stem Cells as Regenerative Therapy for Heart Failure) trial, plasma biomarkers were measured at baseline and at days 7, 30, and 180. Changes were assessed using 2-sample randomization median tests and multivariate 2-sample Cramér-von Mises tests to evaluate time point-specific and trajectory-level effects. Complementary longitudinal mixed-effects models were used to assess treatment×time interactions.
resultsCell therapy induced distinct, time-dependent biomarker changes. Significant reductions were observed in TRAIL-R1 (tumor necrosis factor receptor superfamily member 10A; MSCs+CPCs), IL-33 (interleukin-33), and GDF-15 (growth differentiation factor 15; MSCs, CPCs), PTX3 (pentraxin 3; MSCs, and MSCs+CPCs), TNF-α (tumor necrosis factor-alpha; MSCs and MSCs+CPCs), and PDGF-BB (platelet-derived growth factor-BB; all cell therapy groups). VEGF-A (vascular endothelial growth factor A), HGF (hepatocyte growth factor), and BMP-9 (bone morphogenetic protein 9) also decreased significantly in the MSCs cohort. Multivariate 2-sample Cramér-von Mises test confirmed significant treatment-related shifts in biomarker trajectories for PTX3, TNF-α, PDGF-BB, GDF-15, BMP-9, and MMP-1 (matrix metalloproteinase-1). Complementary longitudinal mixed-effects modeling demonstrated significant treatment×time interactions for TNF-α, MMP-1, and BMP-9. Among individual contrasts, PDGF-BB showed the most consistent treatment effect, including a reduction in the MSCs group versus placebo at day 30 (estimate, -157.98 [95% CI, -286.04 to -29.91];
conclusionsMSCs, CPCs, and their combination are associated with selective, time-dependent modulation of inflammatory and matrix remodeling biomarkers in ischemic heart failure. These findings provide mechanistic insight into cell therapy effects and identify PDGF-BB, PTX3, TNF-α, MMP-1, and BMP-9 as candidate biomarkers for response monitoring and hypothesis generation in future regenerative trials. REGISTRATION: URL: https://clinicaltrials.gov; Unique Identifier: NCT02501811.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.